Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1- piperazinehexanamides: Influence on lipophilicity and 5-HT7 receptor activity. Part III

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5813-5822

  Leopoldo, Marcello ^a   Lacivita, Enza ^a   De Giorgio, Paola ^a   Fracasso, Claudia ^b   Guzzetti, Sara ^b   Caccia, Silvio ^b   Contino, Marialessandra ^a   Colabufo, Nicola A ^a   Berardi, Francesco ^a   Perrone, Roberto ^a  

^a UNIVERSITY OF BARI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; N (4 CYANOPHENYLMETHYL) 4 (2 DIPHENYL) 1 PIPERAZINEHEXANAMIDE; PIPERAZINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN 7 RECEPTOR; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; DEALKYLATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REACTION ANALYSIS; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; MICE; MOLECULAR STRUCTURE; PIPERAZINES; RECEPTORS, SEROTONIN;

EID: 52449084491     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800615e     Document Type: Article

References (51)

1. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 2002, 71, 533-554.
2. 7 receptor research. Trends Pharmacol. Sci. 2004, 25, 481-486.
3. Bickmeyer, U.; Heine, M.; Manzke, T.; Richter, D. W. Differential modulation of Ih by 5-HT receptors in mouse CA1 hippocampal neurons. Eur. J. Neurosci 2002, 16, 209-218.
4. 7 receptors in the mouse suprachiasmatic nucleus. J. Comp. Neurol. 2001, 432, 371-388.
5. 7 receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. J. Chem. Neuroanat. 2001, 21, 63-73.
6. 7) receptor immunoreactivity-positive "stigmoid body"-like structure in developing rat brains. Int. J. Dev. Neurosci 2003, 21, 133-143.
7. 3H]SB-269970. Neurosci. Lett. 2004, 367, 313-316.
8. 7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology 1999, 21, 352-367.
9. 7 receptor suggest therapeutic potential in depression. Neuropharmacology 2005, 48, 492-502.
10. 7 Receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol. Psychiatry 2005, 58, 831-837.
11. 7 receptor antagonist SB-269970 after intrahippocampal administration to rats. Eur. J. Pharmacol. 2006, 553, 185-190.
12. 7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J. Pharmacol. Exp. Ther. 2007, 321, 690-698.
13. 7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder. Neurosci. Lett. 2007, 414, 247-251.
14. 7 receptors during memory consolidation. Behav. Brain Res. 2006, 169, 83-92.
15. 7 receptor antagonists SB-269970 and DR4004 in autoshaping Pavlovian/instrumental learning task. Behav. Brain Res. 2004, 155, 275-282.
16. 7 antagonist SB-269970 in the modulation of working and reference memory in the rat. Behav. Brain Res. 2008, doi: 10.1016/j.bbr.2007.12.020.
17. 7 receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol. Psychiatry 2008, 63, 98-105.
18. 7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav. Pharmacol. 2008, 19, 153-159.
19. 7Rs) and their ligands. Curr. Med. Chem. 2004, 11, 629-661.
20. 7 receptor ligands: recent developments and potential therapeutic applications. Mini Rev. Med. Chem. 2007, 7, 945-960.
21. 7 receptor antagonist. Br. J. Pharmacol. 2000, 130, 539-548.
22. 7 receptor antagonist with improved in vivo properties. Bioorg. Med. Chem. Lett. 2002, 12, 3341-3344.
23. 7R antagonists - implications to selectivity. J. Med. Chem. 2006, 49, 6732-6741.
24. 7 receptor agonism and CoMFA-based modeling of the agonist binding site. J. Med. Chem. 2003, 46, 5365-5374.
25. 7 receptor agonists and antagonists. J. Med. Chem. 2004, 47, 3927-3930.
26. 7 receptor ligands. Bioorg. Med. Chem. Lett. 2007, 17, 3018-3022.
27. 7 receptor agents. J. Med. Chem. 2004, 47, 6616-6624.
28. 7 receptor agents. 2. J. Med. Chem. 2007, 50, 4214-4221.
29. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships. J. Med. Chem. 2006, 49, 7559-7583.
30. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005, 2, 541-553.
31. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, O. A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 1998, 6, 151-165.
32. Chichak, K. S.; Peters, A. J.; Cantrill, S. J.; Stoddart, J. F. Nanoscale borromeates. J. Org. Chem. 2005, 70, 7956-7962.
33. 7 receptor ligands. J. Med. Chem. 2003, 46, 646-649.
34. 1A receptors. J. Pharm. Pharmacol. 2004, 56, 247-255.
35. Caffieri, S. Reversed-phase high-performance liquid chromatography (RP-HPLC) determination of lipophilicity of furocoumarins. Relationship with DNA interaction. J. Pharm. Sci. 2001, 90, 732-739.
36. 7 receptors.
37. 1A/7 receptor agonist 8-OH-DPAT. Neurosci. Lett. 2006, 404, 122-126.
38. Monti, J. M.; Monti, D. The involvement of dopamine in modulation of sleep and waking. Sleep Med. Rev. 2007, 11, 113-133.
39. Caccia, S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr. Drug Metab. 2007, 8, 612-622.
40. Caccia, S. In-vivo metabolism of 4-substituted arylpiperazines to pharmacologically active 1-arylpiperazines. Boll. Chim. Farm. 1990, 129, 183-189.
41. Martin, G. E.; Elgin, R. J., Jr.; Mathiasen, J. R.; Davis, C. B.; Kesslick, J. M.; Baldy, W. J.; Shank, R. P.; DiStefano, D. L.; Fedde, C. L.; Scott, M. K. Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J. Med. Chem. 1989, 32, 1052-1056.
42. Bantle, G. W.; Elworthy, T. R.; Guzman, A.; Jaime-Figueroa, S.; Lopez-Tapia, F. J.; Morgans, D. J.; Perez-Medrano, A.; Pfister, J. R.; Sjogren, E. B.; Talamas, F. X. Preparation of pyrimidinedione, pyrimidinetrione, triazinedione, and tetrahydroquinazolinedione derivatives as α 1-adrenoceptor antagonists. Eur. Pat. Appl. 748800, 1996; Chem. Abstr. 1996, 126, 131468
43. 7b). Br. J. Pharmacol. 1997, 122, 126-132.
44. 1A receptor. J. Biol. Chem. 1989, 264, 14848-14852.
45. 3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 2001, 276, 30308-30314.
46. Carter, D.; Champney, M.; Hwang, B.; Eglen, R. M. Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea pig isolated ileum. Eur. J. Pharmacol. 1995, 280, 243-250.
47. PowerLab/400 (version for Windows); ADInstruments Pty Ltd.: Castle Hill, Australia.
48. de Boer, V. C.; Dihal, A. A.; van der Woude, H.; Arts, I. C.; Wolffram, S.; Alink, G. M.; Rietjens, I. M.; Keijer, J.; Hollman, P. C. Tissue distribution of quercetin in rats and pigs. J. Nutr. 2005, 135, 1718-1725.
49. GraphPad Prism Software (version for Windows); GraphPad Software, Inc.: San Diego, CA.
50. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
51. ClogP 4.0 (version for Windows); BioByte Corp.: Claremont, CA.